Table 4

Scores for neuropsychology measures that declined after PVP for three patients with adverse events on postoperative imaging studies4-150 4-151

MeasurePatient 1Patient 2Patient 3
Pre
Raw (SD)4-152
3 months Raw (SD)12 months Raw (SD)Pre
Raw (SD)
3 months Raw (SD)12months Raw (SD)Pre
Raw (SD)
3 months
Raw (SD)
12 months
Raw (SD)
MMSE282827272729292627
CVLT Total29 (−2.1)24 (−3.2)22 (−3.4)39 (−1.2)30 (−2.8)31 (−2.2)61 (0.60)53 (−0.30)52 (−0.40)
↓−1.1↓−1.3↓−1.6↓−1.0
COWAT28 (−0.30)20 (−1.7)18 (−2.0)43 (0.60)26 (−1.2)19 (−2.0)19 (−0.68)18 (−0.72)21 (−0.40)
↓−1.4↓−1.7↓−1.8↓−2.6
SDMT35 (−2.2)24 (−3.4)21 (−3.8)35 (−2.2)25 (−3.3)27 (−3.1)30 (−2.1)21 (−3.0)29 (−2.2)
↓−1.2↓−1.6↓−1.1
Trails A71 (−3.5)42 (−0.65)55 (−1.9)46 (−1.3)48 (−1.5)38 (−0.39)49 (−0.64)80 (−3.0)73 (−2.5)
↑−2.9↑−1.6↓2.4↓−1.86
Trails B151 (−2.8)288 (−8.0)257 (−6.9)147 (−2.2)164 (−2.8)200 (−4.2)154 (−2.5)199 (−4.1)146 (−2.2)
↓−5.2↓−4.1↓−2.0↓−1.6
WCST Total errors59 (−1.3)84 (−2.5)72 (−2.0)55 (−.57)61 (−0.93)60 (−0.86)51 (−0.95)51 (−0.95)52 (−1.0)
↓−1.2
BDI11344812156
  • 4-150 BNT, CVLT long delay, Hooper, and Stroop interference did not decline greater than 1 SD for three patients;

  • 4-151 see table 2 for description of variables measured;

  • 4-152 SDs are based on published test norms (see table 2 for references); ↓=decline from baseline ⩾1 SD; ↑=improvement from baseline⩾1 SD.